Is Foghorn Therapeutics Stock a Good Investment?
Foghorn Therapeutics Investment Advice | FHTX |
- Examine Foghorn Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Foghorn Therapeutics' leadership team and their track record. Good management can help Foghorn Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Foghorn Therapeutics' business and its evolving consumer preferences.
- Compare Foghorn Therapeutics' performance and market position to its competitors. Analyze how Foghorn Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Foghorn Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Foghorn Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Foghorn Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Foghorn Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Foghorn Therapeutics Stock
Researching Foghorn Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.92. Foghorn Therapeutics had not issued any dividends in recent years.
To determine if Foghorn Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Foghorn Therapeutics' research are outlined below:
| Foghorn Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (86.39 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Wall Street Analysts See a 104.08 percent Upside in Foghorn Therapeutics Can the Stock Really Move This High |
Foghorn Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Foghorn Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Foghorn Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Foghorn Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Foghorn Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-09 | 2022-12-31 | -0.62 | -0.69 | -0.07 | 11 | ||
2022-08-09 | 2022-06-30 | -0.59 | -0.66 | -0.07 | 11 | ||
2024-10-31 | 2024-09-30 | -0.44 | -0.31 | 0.13 | 29 | ||
2022-05-09 | 2022-03-31 | -0.52 | -0.65 | -0.13 | 25 | ||
2024-03-07 | 2023-12-31 | -0.76 | -0.57 | 0.19 | 25 | ||
2024-08-08 | 2024-06-30 | -0.65 | -0.45 | 0.2 | 30 | ||
2022-03-10 | 2021-12-31 | -0.49 | -0.74 | -0.25 | 51 | ||
2023-11-02 | 2023-09-30 | -0.75 | -0.34 | 0.41 | 54 |
Know Foghorn Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Foghorn Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn Therapeutics backward and forwards among themselves. Foghorn Therapeutics' institutional investor refers to the entity that pools money to purchase Foghorn Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alphabet Inc | 2024-09-30 | 500.9 K | State Street Corp | 2024-06-30 | 482.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 399.7 K | Birchview Capital, Lp | 2024-09-30 | 320.9 K | Northern Trust Corp | 2024-09-30 | 250.8 K | The Colony Group Llc | 2024-06-30 | 215.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 130.2 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 129.3 K | Sio Capital Management, Llc | 2024-09-30 | 121.7 K | Flagship Ventures Management, Inc. | 2024-06-30 | 12.7 M | Fmr Inc | 2024-09-30 | 6.3 M |
Foghorn Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 433.07 M.Market Cap |
|
Foghorn Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.47) | (0.50) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 1.28 | 1.34 |
Determining Foghorn Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Foghorn Therapeutics is a good buy. For example, gross profit margin measures Foghorn Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Foghorn Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Foghorn Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Foghorn Therapeutics. Check Foghorn Therapeutics' Beneish M Score to see the likelihood of Foghorn Therapeutics' management manipulating its earnings.
Evaluate Foghorn Therapeutics' management efficiency
Foghorn Therapeutics has return on total asset (ROA) of (0.2045) % which means that it has lost $0.2045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn Therapeutics' management efficiency ratios could be used to measure how well Foghorn Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Foghorn Therapeutics' Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to rise to 0.13 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.84) | (1.75) | |
| Tangible Book Value Per Share | (1.84) | (1.75) | |
| Enterprise Value Over EBITDA | (2.25) | (2.37) | |
| Price Book Value Ratio | (3.51) | (3.33) | |
| Enterprise Value Multiple | (2.25) | (2.37) | |
| Price Fair Value | (3.51) | (3.33) | |
| Enterprise Value | 235.5 M | 223.7 M |
Understanding the operational decisions made by Foghorn Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 3.148 |
Basic technical analysis of Foghorn Stock
As of the 28th of November, Foghorn Therapeutics shows the Coefficient Of Variation of 5116.47, mean deviation of 3.94, and Downside Deviation of 4.5. Foghorn Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Foghorn Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Foghorn Therapeutics' Outstanding Corporate Bonds
Foghorn Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Foghorn Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Foghorn bonds can be classified according to their maturity, which is the date when Foghorn Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Foghorn Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Foghorn Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0235 | |||
| Market Risk Adjusted Performance | 0.0406 | |||
| Mean Deviation | 3.94 | |||
| Semi Deviation | 4.42 | |||
| Downside Deviation | 4.5 | |||
| Coefficient Of Variation | 5116.47 | |||
| Standard Deviation | 5.36 | |||
| Variance | 28.72 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.71) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0306 | |||
| Maximum Drawdown | 34.64 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 8.5 | |||
| Downside Variance | 20.24 | |||
| Semi Variance | 19.54 | |||
| Expected Short fall | (4.30) | |||
| Skewness | 1.43 | |||
| Kurtosis | 5.29 |
| Risk Adjusted Performance | 0.0235 | |||
| Market Risk Adjusted Performance | 0.0406 | |||
| Mean Deviation | 3.94 | |||
| Semi Deviation | 4.42 | |||
| Downside Deviation | 4.5 | |||
| Coefficient Of Variation | 5116.47 | |||
| Standard Deviation | 5.36 | |||
| Variance | 28.72 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.71) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0306 | |||
| Maximum Drawdown | 34.64 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 8.5 | |||
| Downside Variance | 20.24 | |||
| Semi Variance | 19.54 | |||
| Expected Short fall | (4.30) | |||
| Skewness | 1.43 | |||
| Kurtosis | 5.29 |
Consider Foghorn Therapeutics' intraday indicators
Foghorn Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Foghorn Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Foghorn Therapeutics Corporate Filings
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 4th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Foghorn Stock media impact
Far too much social signal, news, headlines, and media speculation about Foghorn Therapeutics that are available to investors today. That information is available publicly through Foghorn media outlets and privately through word of mouth or via Foghorn internal channels. However, regardless of the origin, that massive amount of Foghorn data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Foghorn Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Foghorn Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Foghorn Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Foghorn Therapeutics alpha.
Foghorn Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Foghorn Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Foghorn Therapeutics Corporate Management
| Karin Hellsvik | Corporate VP | Profile | |
| Saurabh Sewak | Vice Development | Profile | |
| Kristian MBA | Chief Officer | Profile | |
| Allan MD | Chief Officer | Profile | |
| Alfonso MD | Chief Officer | Profile |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.